The Silicon Review

Sun Pharma has signed a new agreement with AstraZeneca to develop and distribute cancer/oncology-related drugs to China. A recent report stated that the Indian generic pharmaceutical giant Sun Pharma with AstraZeneca is all set to produce anti-cancer drugs. It also said that Sun Pharma will be taking care of development, regulatory filings, and manufacturing of the products. AstraZeneca will be exclusively responsible for promoting and distributing these products in China.

Sun Pharmaceutical Industries Ltd has also entered into a licensing agreement with AstraZeneca UK Ltd to introduce certain novel and unique ready-to-use infusion oncology and anti-cancerous products for cancer patients in China. The initial time/tenure of the agreement is said to be for 10 years from the day of first commercial sale of the developed products in China, but the financial terms and conditions of the agreement are kept confidential.

“We see a great potential to introduce our specialty and generics products in the growing China market and this licensing agreement is another positive step in that direction,"stated Kal Sundaram, director of corporate development at Sun Pharma, was quoted as saying in the release.

This agreement will help bring cheap and cost-effective drugs to cancer patients in China. The drug quality will be improved, and also will help both the firms to gain popularity and large market value in countries like Asia, Asian-Pacific, and other European countries in the coming time.